Performance of liver stiffness measurements obtained with FibroScan is affected by glucose metabolism in patients with nonalcoholic fatty liver disease
暂无分享,去创建一个
Xin Gao | H. Bian | Shengdi Wu | Mingfeng Xia | Sheng-xiang Rao | Yushan Xu | Hongmei Yan | Xiaopeng Zhu | Xin-xia Chang | Xiaoyang Sun | Xiqi Hu | Liu Wang | X. Yao | Xinyu Yang
[1] Dorairaj Prabhakaran,et al. 2020 International Society of Hypertension global hypertension practice guidelines. , 2020, Journal of hypertension.
[2] Dorairaj Prabhakaran,et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. , 2020, Hypertension.
[3] Xin Gao,et al. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE. , 2020, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[4] Z. Younossi,et al. The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.
[5] D. Semela,et al. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience. , 2019, Swiss medical weekly.
[6] M. Allison,et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. , 2019, Gastroenterology.
[7] B. Neuschwander‐Tetri,et al. Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.
[8] H. Tilg,et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease , 2018, Nature Reviews Gastroenterology & Hepatology.
[9] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[10] R. Hultcrantz,et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. , 2017, Journal of hepatology.
[11] A. Sanyal,et al. Long-term Outcomes in Patients Undergoing Liver Transplantation for Nonalcoholic Steatohepatitis-Related Cirrhosis , 2017, Transplantation.
[12] V. Wong,et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.
[13] Herbert Tilg,et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.
[14] D. S̆timac,et al. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand? , 2016, World journal of gastroenterology.
[15] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[16] E. Tapper,et al. The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease , 2016, The American Journal of Gastroenterology.
[17] T. Yamanaka,et al. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. , 2016, Gastroenterology.
[18] E. Bjornsson,et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.
[19] Ling-jun Kong,et al. Influence of Hepatic Inflammation on FibroScan Findings in Diagnosing Fibrosis in Patients with Chronic Hepatitis B. , 2015, Ultrasound in medicine & biology.
[20] Q. Pan,et al. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[21] H. Cao,et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. , 2014, World journal of gastroenterology.
[22] Y. N. Park,et al. Risk assessment of hepatitis B virus–related hepatocellular carcinoma development using liver stiffness measurement (FibroScan) , 2011, Hepatology.
[23] H. Chan,et al. Factors associated with unreliable liver stiffness measurement and its failure with transient elastography in the Chinese population , 2011, Journal of gastroenterology and hepatology.
[24] B. Neuschwander‐Tetri,et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.
[25] B. Hillner,et al. A decision analysis study of the value of a liver biopsy in nonalcoholic steatohepatitis , 2008, Liver international : official journal of the International Association for the Study of the Liver.
[26] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[27] V. Paradis,et al. Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.
[28] M. Ziol,et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. , 2003, Ultrasound in medicine & biology.
[29] J. Shaw,et al. Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.
[30] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[31] J. Widimský,et al. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1998, Diabetes Care.
[32] [Consensus on clinical application of transient elastography detecting liver fibrosis: a 2018 update]. , 2019, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.
[33] Michael Roden,et al. NAFLD and diabetes mellitus , 2017, Nature Reviews Gastroenterology &Hepatology.
[34] 최은희,et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). , 2011 .
[35] Joel Z Stengel,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.
[36] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[37] J. Bruzzi,et al. Liver biopsy. , 2001, The New England journal of medicine.
[38] A A Bravo,et al. Liver biopsy. , 2001, The New England journal of medicine.